$RZLT
Rezolute, Inc.

2022 Q2 Form 10-Q Financial Statement

#000155837022008563 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.725M $2.068M $2.697M
YoY Change 21.27% 19.54% 1.39%
% of Gross Profit
Research & Development $8.574M $8.686M $9.452M
YoY Change 95.35% 131.13% 110.23%
% of Gross Profit
Depreciation & Amortization $3.000K $3.000K $3.000K
YoY Change 0.0% -70.0%
% of Gross Profit
Operating Expenses $11.30M $10.75M $12.15M
YoY Change 70.27% 96.13% 69.87%
Operating Profit -$10.75M -$12.15M
YoY Change 96.13% 69.87%
Interest Expense $6.142M -$442.0K -$445.0K
YoY Change -1764.5% -124.69% -841.67%
% of Operating Profit
Other Income/Expense, Net -$2.495M -$454.0K -$444.0K
YoY Change -125.39% -907.27%
Pretax Income -$9.423M -$11.21M -$12.59M
YoY Change 45.19% 202.92% 77.37%
Income Tax
% Of Pretax Income
Net Earnings -$9.423M -$11.21M -$12.59M
YoY Change 45.19% 203.33% 77.44%
Net Earnings / Revenue
Basic Earnings Per Share -$0.65 -$0.80
Diluted Earnings Per Share -$298.7K -$0.65 -$0.80
COMMON SHARES
Basic Shares Outstanding 33.58M 17.22M 15.68M
Diluted Shares Outstanding 17.22M 15.68M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.4M $63.42M $77.40M
YoY Change 266.43% 98.24% 105.86%
Cash & Equivalents $150.4M $63.40M $77.40M
Short-Term Investments
Other Short-Term Assets $1.694M $915.0K $695.0K
YoY Change 79.07% 335.71% 26.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $152.1M $64.33M $78.10M
YoY Change 262.21% 99.79% 104.71%
LONG-TERM ASSETS
Property, Plant & Equipment $16.00K $19.00K $22.00K
YoY Change -44.83% -96.27% -96.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $148.0K $5.048M $5.048M
YoY Change -22.51% 2094.78% 2869.41%
Total Long-Term Assets $316.0K $5.242M $5.307M
YoY Change -48.7% 618.08% 607.6%
TOTAL ASSETS
Total Short-Term Assets $152.1M $64.33M $78.10M
Total Long-Term Assets $316.0K $5.242M $5.307M
Total Assets $152.4M $69.57M $83.41M
YoY Change 257.72% 111.28% 114.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.132M $1.557M $4.349M
YoY Change 9.37% 92.22% 612.95%
Accrued Expenses $108.0K $557.0K $1.619M
YoY Change -68.42% 11.4% 2.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.500M $2.900M $6.400M
YoY Change 27.03% -19.22% 133.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $14.29M $14.18M
YoY Change -100.0%
Other Long-Term Liabilities $487.0K $502.0K $517.0K
YoY Change -15.16% 139.05% 84.64%
Total Long-Term Liabilities $487.0K $14.79M $14.70M
YoY Change -96.65% 6941.9% 5148.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.500M $2.900M $6.400M
Total Long-Term Liabilities $487.0K $14.79M $14.70M
Total Liabilities $2.949M $17.67M $21.14M
YoY Change -82.14% 364.89% 600.0%
SHAREHOLDERS EQUITY
Retained Earnings -$209.2M -$199.8M -$188.6M
YoY Change 24.42%
Common Stock $34.00K $16.00K $16.00K
YoY Change 325.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $149.5M $51.91M $62.27M
YoY Change
Total Liabilities & Shareholders Equity $152.4M $69.57M $83.41M
YoY Change 257.72% 111.28% 114.41%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$9.423M -$11.21M -$12.59M
YoY Change 45.19% 203.33% 77.44%
Depreciation, Depletion And Amortization $3.000K $3.000K $3.000K
YoY Change 0.0% -70.0%
Cash From Operating Activities -$12.11M -$13.97M -$7.197M
YoY Change 131.5% 158.67% 14.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 94.10M -19.00K 52.31M
YoY Change 558.85% -90.95% 39.64%
NET CHANGE
Cash From Operating Activities -12.11M -13.97M -7.197M
Cash From Investing Activities 0.000
Cash From Financing Activities 94.10M -19.00K 52.31M
Net Change In Cash 81.99M -13.99M 45.11M
YoY Change 805.81% 149.32% 44.59%
FREE CASH FLOW
Cash From Operating Activities -$12.11M -$13.97M -$7.197M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001509261
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17218000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8352000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13748000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7445000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8352000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15556000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.94
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8352000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity File Number
EntityFileNumber
001-39683
dei Entity Registrant Name
EntityRegistrantName
REZOLUTE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3440894
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Redwood Shores Parkway, Suite 315
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
206-4507
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RZLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33582831
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63416000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41047000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
915000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
946000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
64331000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
41993000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5000000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
175000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
396000
CY2022Q1 us-gaap Deferred Costs
DeferredCosts
48000
CY2021Q2 us-gaap Deferred Costs
DeferredCosts
191000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29000
CY2022Q1 us-gaap Assets
Assets
69573000
CY2021Q2 us-gaap Assets
Assets
42609000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1557000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1035000
CY2021Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
242000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
450000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
77000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
764000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
349000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
107000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
265000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2878000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1968000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
14286000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
13968000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
187000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15556000
CY2022Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
395000
CY2021Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
387000
CY2022Q1 us-gaap Liabilities
Liabilities
17666000
CY2021Q2 us-gaap Liabilities
Liabilities
16510000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
400000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
400000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8352000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
251666000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
194229000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199775000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168138000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
51907000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
26099000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69573000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42609000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8686000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3758000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23912000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10598000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2068000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1725000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6632000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5660000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
10754000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
5483000
us-gaap Operating Expenses
OperatingExpenses
30544000
us-gaap Operating Expenses
OperatingExpenses
16258000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10754000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5483000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30544000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16258000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-442000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1329000
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-12000
CY2021Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1784000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-8000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1784000
rzlt Employee Retention Credit From Federal And State Governments Financial Assistance Cares Act
EmployeeRetentionCreditFromFederalAndStateGovernmentsFinancialAssistanceCaresAct
231000
us-gaap Interest And Other Income
InterestAndOtherIncome
13000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13748000
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
4000
us-gaap Interest And Other Income
InterestAndOtherIncome
62000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-454000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1788000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1093000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1846000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11208000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3695000
us-gaap Net Income Loss
NetIncomeLoss
-31637000
us-gaap Net Income Loss
NetIncomeLoss
-14412000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.94
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17218000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8352000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7445000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
26099000
rzlt Proceeds From Issuance Of Common Stock Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockUnderwrittenPublicOffering
39956000
rzlt Pre Funded Warrants
PreFundedWarrants
10783000
rzlt Gross Proceeds From Issuance Of Common Stock For Cash Registered Direct Offering
GrossProceedsFromIssuanceOfCommonStockForCashRegisteredDirectOffering
5000000
rzlt Gross Proceeds From Issuance Of Common Stock For Cash Under Equity Distribution Agreement Value
GrossProceedsFromIssuanceOfCommonStockForCashUnderEquityDistributionAgreementValue
1519000
rzlt Gross Proceeds From Issuance Of Common Stock For Cash In Under Lpc Purchase Agreement
GrossProceedsFromIssuanceOfCommonStockForCashInUnderLpcPurchaseAgreement
1172000
rzlt Stock Issuance Cost
StockIssuanceCost
4136000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2701000
rzlt Commitment Shares Issued Under Lpc Purchase Agreement
CommitmentSharesIssuedUnderLpcPurchaseAgreement
450000
us-gaap Net Income Loss
NetIncomeLoss
-31637000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
51907000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7365000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2305000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
8000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3550000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7000
rzlt Adjustment To Additional Paid In Capital Reclassification Of Derivative Liability For Authorized Share Deficiency
AdjustmentToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityForAuthorizedShareDeficiency
3591000
us-gaap Net Income Loss
NetIncomeLoss
-14412000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
29132000
us-gaap Profit Loss
ProfitLoss
-31637000
us-gaap Profit Loss
ProfitLoss
-14412000
us-gaap Share Based Compensation
ShareBasedCompensation
2701000
us-gaap Share Based Compensation
ShareBasedCompensation
2305000
rzlt Accretion Of Debt Discount And Issuance Costs
AccretionOfDebtDiscountAndIssuanceCosts
-319000
rzlt Non Cash Lease Expense
NonCashLeaseExpense
221000
rzlt Non Cash Lease Expense
NonCashLeaseExpense
214000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-8000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1784000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8000
rzlt Fair Value Adjustment Of Shares
FairValueAdjustmentOfShares
7000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-376000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
548000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-81000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
307000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41047000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-45000
rzlt Increase Decrease In License Fee Payable
IncreaseDecreaseInLicenseFeePayable
-1809000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27506000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15211000
rzlt Proceeds From Underwritten Public Offering
ProceedsFromUnderwrittenPublicOffering
50738000
rzlt Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
5000000
rzlt Proceeds From Issuance Of Units
ProceedsFromIssuanceOfUnits
41000000
rzlt Payments For Professional Fees And Other Offering Costs
PaymentsForProfessionalFeesAndOtherOfferingCosts
3449000
rzlt Payments For Professional Fees And Other Offering Costs
PaymentsForProfessionalFeesAndOtherOfferingCosts
3680000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
104000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
75000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2690000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54875000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37245000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27369000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22034000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9955000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68416000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31989000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63416000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31989000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5000000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68416000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31989000
us-gaap Interest Paid Net
InterestPaidNet
1011000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
302000
us-gaap Operating Lease Payments
OperatingLeasePayments
254000
us-gaap Operating Lease Payments
OperatingLeasePayments
275000
us-gaap Stock Issued1
StockIssued1
450000
rzlt Adjustment To Additional Paid In Capital Reclassification Of Derivative Liability For Authorized Share Deficiency
AdjustmentToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityForAuthorizedShareDeficiency
3591000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
16000
rzlt Furniture And Equipment Received As Inducement Under Operating Lease
FurnitureAndEquipmentReceivedAsInducementUnderOperatingLease
10000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rezolute, Inc. (the “Company”) is a clinical stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance.</p>
rzlt Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, the fair value of derivative liabilities, fair value of share-based payments, management’s assessment of going concern, and clinical trial accrued liabilities. Actual results could differ from those estimates.</p>
us-gaap Net Income Loss
NetIncomeLoss
-31600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27500000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20900000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20400000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199800000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63400000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2900000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2900000
CY2021Q4 rzlt Net Proceeds From Offering
NetProceedsFromOffering
52300000
CY2021Q4 rzlt Net Proceeds From Offering
NetProceedsFromOffering
52300000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2700000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63400000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
175000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
396000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
107000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
265000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
187000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
214000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
452000
CY2021Q1 rzlt Financial Instruments Subject To Mandatory Redemption Settlement Terms Weighted Average Fair Value Per Share
FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsWeightedAverageFairValuePerShare
4.60
rzlt Financial Instruments Subject To Mandatory Redemption Settlement Terms Weighted Average Fair Value Per Share
FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsWeightedAverageFairValuePerShare
2.44
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
3591000
CY2022Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
1807000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
833000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
98000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
103000
us-gaap Operating Lease Cost
OperatingLeaseCost
291000
us-gaap Operating Lease Cost
OperatingLeaseCost
268000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
29000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
117000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
79000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
225000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
214000
CY2021Q2 rzlt Number Of Tranches
NumberOfTranches
3
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5000000.0
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
4880000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15713000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1427000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
14286000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62265000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
850000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11208000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
51907000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35886000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
530000
CY2021Q1 rzlt Adjustment To Additional Paid In Capital Reclassification Of Derivative Liability For Authorized Share Deficiency
AdjustmentToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityForAuthorizedShareDeficiency
3591000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3695000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
29132000
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
10800000
rzlt Minimum Period For Increase Or Decrease In Ownership Percentage
MinimumPeriodForIncreaseOrDecreaseInOwnershipPercentage
P61D
CY2022Q1 rzlt Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8352000
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2428000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
780000
CY2021Q1 rzlt Expiration Of Stock Options And Warrants
ExpirationOfStockOptionsAndWarrants
780000
CY2021Q1 rzlt Number Of Shares Subject To Deficiency Required To Settle In Cash
NumberOfSharesSubjectToDeficiencyRequiredToSettleInCash
780000
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
3600000
rzlt Expiration Of Stock Options And Warrants
ExpirationOfStockOptionsAndWarrants
40000
CY2021Q1 rzlt Number Of Shares Subject To Deficiency Required To Settle In Cash
NumberOfSharesSubjectToDeficiencyRequiredToSettleInCash
740000
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
740000
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
1800000
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
780000
CY2022Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
740000
CY2021Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
1800000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000.0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000.0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
118000
rzlt Share Based Payment Arrangement Option Shares Authorized Outstanding And Available For Future Grants
ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Presented below is a summary of the number of shares authorized, outstanding, and available for future grants under each of the Company’s stock option plans as of March 31, 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Available</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2015 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">July 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118</p></td></tr></table>
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1705000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1587000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1285000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
421000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
61000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
20.19
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
58000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.28
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1587000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
620000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
19.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
850000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
530000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2701000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2305000
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
17218000
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
8352000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13748000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7445000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2748000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2311000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68400000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41000000.0
CY2022Q1 rzlt Lessee Operating Lease Not Yet Commenced Liability To Be Paid Remainder Of Fiscal Year
LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear
50000
CY2022Q1 rzlt Lessee Operating Lease Not Yet Commenced Liability To Be Paid Year One
LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearOne
199000
CY2022Q1 rzlt Lessee Operating Lease Not Yet Commenced Liability To Be Paid Year Two
LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearTwo
614000
CY2022Q1 rzlt Lessee Operating Lease Not Yet Commenced Liability To Be Paid Year Three
LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidYearThree
632000
CY2022Q1 rzlt Lessee Operating Lease Not Yet Commenced Liability To Be Paid After Year Three
LesseeOperatingLeaseNotYetCommencedLiabilityToBePaidAfterYearThree
1377000
CY2022Q1 rzlt Lessee Operating Lease Lease Not Yet Commenced Liability
LesseeOperatingLeaseLeaseNotYetCommencedLiability
2872000

Files In Submission

Name View Source Status
0001558370-22-008563-index-headers.html Edgar Link pending
0001558370-22-008563-index.html Edgar Link pending
0001558370-22-008563.txt Edgar Link pending
0001558370-22-008563-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rzlt-20220331.xsd Edgar Link pending
rzlt-20220331x10q.htm Edgar Link pending
rzlt-20220331x10q_htm.xml Edgar Link completed
rzlt-20220331xex31d1.htm Edgar Link pending
rzlt-20220331xex32d1.htm Edgar Link pending
rzlt-20220331_cal.xml Edgar Link unprocessable
rzlt-20220331_def.xml Edgar Link unprocessable
rzlt-20220331_lab.xml Edgar Link unprocessable
rzlt-20220331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending